^
Association details:
| Biomarker: | MYC amplification |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | eprenetapopt (APR-246) (p53 reactivator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Investigation of APR-246 in Small Cell Lung Cancer
Published date:
02/11/2022
Excerpt:
Interestingly, within our SCLC panel, there is a significant proportion of variant SCLC harboring c-myc amplification that are exquisitely sensitive to APR-246...APR-246 harbors excellent single agent in vitro anti-tumor efficacy across SCLC transcriptional subtypes.
